Cogent Biosciences (COGT) to Release Earnings on Tuesday

Key Points

• Cogent Biosciences is slated to announce its Q2 2025 earnings on August 5th, with analysts predicting a loss of ($0.54) per share for the quarter.
• The stock price of Cogent Biosciences opened at $12.09, with a market cap of $1.38 billion and a recent trading range between $3.72 and $12.97 over the past year.
• Institutional interest is increasing, with firms like AQR Capital Management and Goldman Sachs significantly boosting their stakes in Cogent Biosciences during Q1.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.04. On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Cogent Biosciences Price Performance

COGT stock traded down $0.02 during trading on Friday, hitting $11.40. 1,474,464 shares of the stock traded hands, compared to its average volume of 2,029,956. Cogent Biosciences has a 1 year low of $3.72 and a 1 year high of $12.97. The firm's 50 day moving average is $8.49 and its two-hundred day moving average is $7.23. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -6.20 and a beta of 1.88.

Insider Transactions at Cogent Biosciences

In other Cogent Biosciences news, Director Fairmount Funds Management Llc bought 2,777,777 shares of Cogent Biosciences stock in a transaction dated Thursday, July 10th. The stock was acquired at an average cost of $9.00 per share, with a total value of $24,999,993.00. Following the purchase, the director directly owned 9,003,418 shares in the company, valued at $81,030,762. This represents a 44.62% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 7.29% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Strs Ohio purchased a new stake in shares of Cogent Biosciences during the first quarter worth approximately $36,000. Jane Street Group LLC grew its holdings in shares of Cogent Biosciences by 66.2% during the first quarter. Jane Street Group LLC now owns 123,822 shares of the technology company's stock worth $742,000 after buying an additional 49,338 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Cogent Biosciences by 14.3% during the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company's stock worth $5,924,000 after buying an additional 124,069 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Cogent Biosciences by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company's stock worth $377,000 after buying an additional 3,693 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Cogent Biosciences by 482.6% during the first quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company's stock worth $963,000 after buying an additional 133,174 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on COGT shares. JPMorgan Chase & Co. increased their price objective on shares of Cogent Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research note on Thursday, July 10th. Wedbush restated a "neutral" rating and set a $10.00 target price on shares of Cogent Biosciences in a research note on Monday, June 30th. HC Wainwright raised their target price on shares of Cogent Biosciences from $12.00 to $22.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Leerink Partners raised their target price on shares of Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday, July 7th. Finally, Citigroup raised their target price on shares of Cogent Biosciences from $15.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, July 18th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Cogent Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $18.70.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.